Powered by lexis nexis

BIOPHYTIS completes a ‚¬10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates

Oct 11, 2017 - GlobeNewswire

PARIS, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announces entry into definitive agreements for a ‚¬ 10.4 million capital raise via the issuance of new ordinary shares without shareholders' preferential subscription rights and reserved to institutional investors in Europe and the United States.

Stanislas Veillet, Chairman and Chief Executive Office...